MBX Biosciences, Inc. Common Stock (MBX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $63.08 (-1.27%), Market cap $1.51B, 52-week low–high $9.73 ~ $43.14.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate,
Financial statements, price targets, institutional (13F) holdings and related news for MBX Biosciences, Inc. Common Stock are updated in real time on BlackAll Trade.
MBX Biosciences, Inc. Common Stock trades at $63.08 (-1.27%). Real-time quotes and charts are available on BlackAll Trade.
MBX Biosciences, Inc. Common Stock has a market cap of about $1.51B.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its l